Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Gut microbiota shape 'inflamm-ageing' cytokines and account for age-dependent decline in DNA damage repair.

Guedj A, Volman Y, Geiger-Maor A, Bolik J, Schumacher N, Künzel S, Baines JF, Nevo Y, Elgavish S, Galun E, Amsalem H, Schmidt-Arras D, Rachmilewitz J.

Gut. 2019 Oct 5. pii: gutjnl-2019-318491. doi: 10.1136/gutjnl-2019-318491. [Epub ahead of print]

PMID:
31586932
2.

Identification of the novel HLA-B allele, HLA-B*15:539, in a South-Sudanese individual.

Benedek G, Abed El-Latif M, Miller K, Galun E, Levite M.

HLA. 2019 Oct;94(4):380-381. doi: 10.1111/tan.13624. Epub 2019 Jul 24.

PMID:
31271260
3.

Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.

Potikha T, Pappo O, Mizrahi L, Olam D, Maller SM, Rabinovich GA, Galun E, Goldenberg DS.

FASEB J. 2019 Jul;33(7):7995-8007. doi: 10.1096/fj.201900017R. Epub 2019 Mar 21.

PMID:
30897344
4.

High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.

Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, Nimer A, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y, Mendelson E, Mor O.

Antivir Ther. 2019;24(3):221-228. doi: 10.3851/IMP3301.

PMID:
30880684
5.

Transparent Polycrystalline Magnesium Aluminate Spinel Fabricated by Spark Plasma Sintering.

Sokol M, Ratzker B, Kalabukhov S, Dariel MP, Galun E, Frage N.

Adv Mater. 2018 Oct;30(41):e1706283. doi: 10.1002/adma.201706283. Epub 2018 Jun 19. Review.

PMID:
29920779
6.

Primary sclerosing cholangitis is associated with abnormalities in CFTR.

Werlin S, Scotet V, Uguen K, Audrezet MP, Cohen M, Yaakov Y, Safadi R, Ilan Y, Konikoff F, Galun E, Mizrahi M, Slae M, Sayag S, Cohen-Cymberknoh M, Wilschanski M, Ferec C.

J Cyst Fibros. 2018 Sep;17(5):666-671. doi: 10.1016/j.jcf.2018.04.005. Epub 2018 May 26.

PMID:
29807875
7.

Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins.

Ahmed M, Kumar G, Gourevitch S, Levchenko T, Galun E, Torchilin V, Goldberg SN.

Int J Hyperthermia. 2018 Nov;34(7):934-942. doi: 10.1080/02656736.2018.1462535. Epub 2018 Apr 24.

PMID:
29631466
8.

Reply.

Chai C, Galun E, Giladi H.

Gastroenterology. 2018 Apr;154(5):1553-1554. doi: 10.1053/j.gastro.2018.03.018. Epub 2018 Mar 8. No abstract available.

PMID:
29526723
9.

Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity.

Stoyanov E, Mizrahi L, Olam D, Schnitzer-Perlman T, Galun E, Goldenberg DS.

Oncotarget. 2017 May 30;8(62):104772-104784. doi: 10.18632/oncotarget.18300. eCollection 2017 Dec 1.

10.

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.

Klein S, Abraham M, Bulvik B, Dery E, Weiss ID, Barashi N, Abramovitch R, Wald H, Harel Y, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Pereg Y, Peled A.

Cancer Res. 2018 Mar 15;78(6):1471-1483. doi: 10.1158/0008-5472.CAN-17-0454. Epub 2017 Dec 19.

11.

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation.

Abraham M, Wald H, Vaizel-Ohayon D, Grabovsky V, Oren Z, Karni A, Weiss L, Galun E, Peled A, Eizenberg O.

Front Immunol. 2017 Nov 23;8:1432. doi: 10.3389/fimmu.2017.01432. eCollection 2017.

12.

Split2 Protein-Ligation Generates Active IL-6-Type Hyper-Cytokines from Inactive Precursors.

Moll JM, Wehmöller M, Frank NC, Homey L, Baran P, Garbers C, Lamertz L, Axelrod JH, Galun E, Mootz HD, Scheller J.

ACS Synth Biol. 2017 Dec 15;6(12):2260-2272. doi: 10.1021/acssynbio.7b00208. Epub 2017 Nov 29.

PMID:
29136368
13.

A Protective Function of IL-22BP in Ischemia Reperfusion and Acetaminophen-Induced Liver Injury.

Kleinschmidt D, Giannou AD, McGee HM, Kempski J, Steglich B, Huber FJ, Ernst TM, Shiri AM, Wegscheid C, Tasika E, Hübener P, Huber P, Bedke T, Steffens N, Agalioti T, Fuchs T, Noll J, Lotter H, Tiegs G, Lohse AW, Axelrod JH, Galun E, Flavell RA, Gagliani N, Huber S.

J Immunol. 2017 Dec 15;199(12):4078-4090. doi: 10.4049/jimmunol.1700587. Epub 2017 Nov 6.

14.

Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.

Kumar G, Goldberg SN, Gourevitch S, Levchenko T, Torchilin V, Galun E, Ahmed M.

Radiology. 2018 Feb;286(2):524-536. doi: 10.1148/radiol.2017162943. Epub 2017 Sep 6.

15.

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers.

Abraham M, Pereg Y, Bulvik B, Klein S, Mishalian I, Wald H, Eizenberg O, Beider K, Nagler A, Golan R, Vainstein A, Aharon A, Galun E, Caraco Y, Or R, Peled A.

Clin Cancer Res. 2017 Nov 15;23(22):6790-6801. doi: 10.1158/1078-0432.CCR-16-2919. Epub 2017 Aug 23.

16.

Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues.

Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R, Shpitzen S, Udi S, Tam J, Heeren J, Worthmann A, Schramm C, Kluwe J, Ravid R, Hornstein E, Giladi H, Galun E.

Gastroenterology. 2017 Nov;153(5):1404-1415. doi: 10.1053/j.gastro.2017.08.013. Epub 2017 Aug 9.

PMID:
28802563
17.

Correction: Early age decline in DNA repair capacity in the liver: in depth profile of differential gene expression.

Guedj A, Geiger-Maor A, Benyamini H, Nevo Y, Elgavish S, Galun E, Amsalem H, Rachmilewitz J.

Aging (Albany NY). 2017 May 30;9(6):1640. doi: 10.18632/aging.101242. No abstract available.

18.

Brain neurotransmitters in an animal model with postpartum depressive-like behavior.

Avraham Y, Hants Y, Vorobeiv L, Staum M, Abu Ahmad W, Mankuta D, Galun E, Arbel-Alon S.

Behav Brain Res. 2017 May 30;326:307-321. doi: 10.1016/j.bbr.2017.01.013. Epub 2017 Mar 12.

PMID:
28300619
19.

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A.

Leukemia. 2017 Nov;31(11):2336-2346. doi: 10.1038/leu.2017.82. Epub 2017 Mar 10.

PMID:
28280274
20.

Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis.

Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M, Goldenberg D, Sonnenblick A, Peled A, Rose-John S, Galun E, Axelrod JH.

Hepatology. 2017 May;65(5):1600-1611. doi: 10.1002/hep.29004. Epub 2017 Mar 23.

PMID:
28027584
21.

Early age decline in DNA repair capacity in the liver: in depth profile of differential gene expression.

Guedj A, Geiger-Maor A, Galun E, Benyamini H, Nevo Y, Elgavish Sh, Amsalem H, Rachmilewitz J.

Aging (Albany NY). 2016 Nov 30;8(11):3131-3146. doi: 10.18632/aging.101120. Erratum in: Aging (Albany NY). 2017 May 30;9(6):1640.

22.

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.

Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, Ribakovsky E, Klein S, Olam D, Weiss L, Wald H, Abraham M, Galun E, Peled A, Nagler A.

Clin Cancer Res. 2017 Apr 1;23(7):1733-1747. doi: 10.1158/1078-0432.CCR-15-2618. Epub 2016 Oct 3.

23.

The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.

Simerzin A, Zorde-Khvalevsky E, Rivkin M, Adar R, Zucman-Rossi J, Couchy G, Roskams T, Govaere O, Oren M, Giladi H, Galun E.

Hepatology. 2016 Nov;64(5):1623-1636. doi: 10.1002/hep.28679. Epub 2016 Jul 25.

PMID:
27302319
24.

Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia.

Rivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval JB, Rosenberg N, Harari-Steinfeld R, Schneider R, Amir G, Condiotti R, Heikenwalder M, Weber A, Schramm C, Wege H, Kluwe J, Galun E, Giladi H.

Gastroenterology. 2016 Nov;151(5):999-1010.e3. doi: 10.1053/j.gastro.2016.07.031. Epub 2016 Jul 29.

25.

Response.

Chapiro J, Goldberg SN, Galun E, Geschwind JF.

Radiology. 2016 Apr;279(1):323. No abstract available.

PMID:
27437552
26.

Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.

Bulvik BE, Rozenblum N, Gourevich S, Ahmed M, Andriyanov AV, Galun E, Goldberg SN.

Radiology. 2016 Aug;280(2):413-24. doi: 10.1148/radiol.2015151166. Epub 2016 Jan 27.

PMID:
27429143
27.

Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.

Kumar G, Goldberg SN, Wang Y, Velez E, Gourevitch S, Galun E, Ahmed M.

Eur Radiol. 2017 Mar;27(3):1238-1247. doi: 10.1007/s00330-016-4405-4. Epub 2016 Jun 10.

PMID:
27287478
28.

Galectin-1 is essential for efficient liver regeneration following hepatectomy.

Potikha T, Ella E, Cerliani JP, Mizrahi L, Pappo O, Rabinovich GA, Galun E, Goldenberg DS.

Oncotarget. 2016 May 31;7(22):31738-54. doi: 10.18632/oncotarget.9194.

29.

Radiation-Induced Loss of Salivary Gland Function Is Driven by Cellular Senescence and Prevented by IL6 Modulation.

Marmary Y, Adar R, Gaska S, Wygoda A, Maly A, Cohen J, Eliashar R, Mizrachi L, Orfaig-Geva C, Baum BJ, Rose-John S, Galun E, Axelrod JH.

Cancer Res. 2016 Mar 1;76(5):1170-80. doi: 10.1158/0008-5472.CAN-15-1671. Epub 2016 Jan 12. Erratum in: Cancer Res. 2016 May 1;76(9):2846.

30.

Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.

Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A.

Oncotarget. 2016 Jan 26;7(4):4860-70. doi: 10.18632/oncotarget.6638.

31.

Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma.

Galun E.

Hepatology. 2016 Feb;63(2):354-6. doi: 10.1002/hep.28344. Epub 2015 Dec 18. No abstract available.

PMID:
26566854
32.

Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition.

Ahmed M, Kumar G, Moussa M, Wang Y, Rozenblum N, Galun E, Goldberg SN.

Radiology. 2016 Apr;279(1):103-17. doi: 10.1148/radiol.2015150080. Epub 2015 Sep 29.

33.

The knockdown of H19lncRNA reveals its regulatory role in pluripotency and tumorigenesis of human embryonic carcinoma cells.

Zeira E, Abramovitch R, Meir K, Even Ram S, Gil Y, Bulvik B, Bromberg Z, Levkovitch O, Nahmansson N, Adar R, Reubinoff B, Galun E, Gropp M.

Oncotarget. 2015 Oct 27;6(33):34691-703. doi: 10.18632/oncotarget.5787.

34.

Correction: Gene Transfer to Chicks Using Lentiviral Vectors Administered via the Embryonic Chorioallantoic Membrane.

Hen G, Yosefi S, Shinder D, Or A, Mygdal S, Condiotti R, Galun E, Bor A, Sela-Donenfeld D, Friedman-Einat M.

PLoS One. 2015 Sep 14;10(9):e0138629. doi: 10.1371/journal.pone.0138629. eCollection 2015. No abstract available.

35.

Oncogenesis: An "Off-Target" Effect of Radiofrequency Ablation.

Rozenblum N, Zeira E, Scaiewicz V, Bulvik B, Gourevitch S, Yotvat H, Galun E, Goldberg SN.

Radiology. 2015 Aug;276(2):426-32. doi: 10.1148/radiol.2015141695.

PMID:
26203709
36.

Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.

Ahmed M, Kumar G, Navarro G, Wang Y, Gourevitch S, Moussa MH, Rozenblum N, Levchenko T, Galun E, Torchilin VP, Goldberg SN.

PLoS One. 2015 Jul 8;10(7):e0128910. doi: 10.1371/journal.pone.0128910. eCollection 2015.

37.

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.

Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E.

Oncotarget. 2015 Sep 15;6(27):24560-70.

38.

Macrophages Regulate the Systemic Response to DNA Damage by a Cell Nonautonomous Mechanism.

Geiger-Maor A, Guedj A, Even-Ram S, Smith Y, Galun E, Rachmilewitz J.

Cancer Res. 2015 Jul 1;75(13):2663-73. doi: 10.1158/0008-5472.CAN-14-3635. Epub 2015 May 14.

39.

Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis.

Stoyanov E, Ludwig G, Mizrahi L, Olam D, Schnitzer-Perlman T, Tasika E, Sass G, Tiegs G, Jiang Y, Nie T, Kohler J, Schinazi RF, Vertino PM, Cedar H, Galun E, Goldenberg D.

Oncotarget. 2015 May 10;6(13):11047-60.

40.

Radiofrequency Ablation: Inflammatory Changes in the Periablative Zone Can Induce Global Organ Effects, including Liver Regeneration.

Rozenblum N, Zeira E, Bulvik B, Gourevitch S, Yotvat H, Galun E, Goldberg SN.

Radiology. 2015 Aug;276(2):416-25. doi: 10.1148/radiol.15141918. Epub 2015 Mar 30.

PMID:
25822472
41.

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.

Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A, Nagler A.

Oncotarget. 2014 Nov 30;5(22):11283-96.

42.

Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver.

Ella E, Heim D, Stoyanov E, Harari-Steinfeld R, Steinfeld I, Pappo O, Perlman TS, Nachmansson N, Rivkin L, Olam D, Abramovitch R, Wege H, Galun E, Goldenberg D.

Oncotarget. 2014 Nov 15;5(21):10318-31.

43.

MicroRNA editing facilitates immune elimination of HCMV infected cells.

Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, Galun E, Horejsi V, Isakov O, Shomron N, Wolf DG, Hengel H, Mandelboim O.

PLoS Pathog. 2014 Feb 27;10(2):e1003963. doi: 10.1371/journal.ppat.1003963. eCollection 2014 Feb.

44.

Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.

Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A.

Mol Cancer Ther. 2014 May;13(5):1155-69. doi: 10.1158/1535-7163.MCT-13-0410. Epub 2014 Feb 6.

45.

Natural killer cell-dependent anti-fibrotic pathway in liver injury via Toll-like receptor-9.

Abu-Tair L, Axelrod JH, Doron S, Ovadya Y, Krizhanovsky V, Galun E, Amer J, Safadi R.

PLoS One. 2013 Dec 10;8(12):e82571. doi: 10.1371/journal.pone.0082571. eCollection 2013.

46.

Mutant KRAS is a druggable target for pancreatic cancer.

Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2.

47.

The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.

Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A.

Clin Cancer Res. 2014 Jan 15;20(2):469-79. doi: 10.1158/1078-0432.CCR-13-1302. Epub 2013 Nov 18.

48.

Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.

Condiotti R, Goldenberg D, Giladi H, Schnitzer-Perlman T, Waddington SN, Buckley SM, Heim D, Cheung W, Themis M, Coutelle C, Simerzin A, Osejindu E, Wege H, Themis M, Galun E.

Mol Ther. 2014 Jan;22(1):59-68. doi: 10.1038/mt.2013.193. Epub 2013 Aug 28.

49.

MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G.

J Clin Invest. 2013 Jun;123(6):2703-18.

50.

Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A.

Clin Cancer Res. 2013 Jul 1;19(13):3495-507. doi: 10.1158/1078-0432.CCR-12-3015. Epub 2013 May 1.

Supplemental Content

Support Center